Last updated: February 14, 2026
Product Overview
NDC 62559-0680 refers to COVID-19 antibody cocktail treatment developed by Regeneron Pharmaceuticals, known as casirivimab and imdevimab. It is authorized for emergency use in hospitalized or at-risk patients to treat COVID-19. The medication is administered via infusion, with dosing and administration guided by CDC and FDA protocols.
Market Size
The COVID-19 therapeutic market remains dynamic. Key drivers include:
- Ongoing vaccination efforts boosting treatment needs for breakthrough cases.
- Variants of concern requiring targeted monoclonal antibody (mAb) therapies.
- Increasing adoption in outpatient settings for early intervention.
Recent data indicate:
- The U.S. primary market includes approximately 1 million to 1.2 million COVID-19 cases monthly, with a subset eligible for antibody therapies.
- Estimated eligible patients for monoclonal antibody treatment range from 300,000 to 600,000 monthly during peak periods (CDC reporting) [1].
Global expansion is limited by distribution infrastructure, regulatory approvals, and competitive landscape. Major markets include the U.S., Europe, and select Asia-Pacific countries, with U.S. leading due to expedited emergency use authorizations.
Pricing Structures and Reimbursement
The per-dose list price of casirivimab/imdevimab has historically ranged between $850 and $2,100 depending on contracts and payers. For example:
| Aspect |
Details |
| U.S. Average Wholesale Price (AWP) |
Approximately $2,100 per infusion (per dose) [2] |
| Actual Reimbursement |
Varies; Medicare/Medicaid reimbursements generally align with negotiated rates. |
| Commercial Payers |
Contracted pricing can average ~$850 - $1,200 per dose depending on volume and agreements. |
The treatment involves a single infusion, with two doses often administered, totaling up to $4,200 per patient based on list pricing. However, extended discounts and discounts via federal programs have reduced net prices.
Market Dynamics and Competitive Landscape
Key competitors include similar monoclonal antibody treatments such as Eli Lilly's bamlanivimab/etesevimab, AstraZeneca's tixagevimab/cilgavimab, and emerging oral antivirals like Pfizer's Paxlovid.
Market share varies with efficacy against variants:
- The efficacy of casirivimab/imdevimab diminishes against certain variants such as Omicron.
- Regulatory restrictions have limited use in some regions, shifting demand.
Price Projections
Forecasts are contingent on pandemic trajectory, variant evolution, and regulatory landscape:
| Year |
Estimated Market Size |
Projected Price Range |
Notes |
| 2023 |
$1.8 billion – $2.3 billion |
$850 – $2,100 per dose |
Steady demand pre-variant emergence; supply chain stabilizes. |
| 2024 |
$1.2 billion – $2 billion |
$850 – $2,100 per dose |
Reduced demand if new variants diminish treatment efficacy. |
| 2025 |
$800 million – $1.5 billion |
$700 – $1,800 per dose |
Shift toward oral therapies and booster focus. |
Pricing pressure will increase due to:
- Competition from oral antivirals with easier administration.
- Contract negotiations, especially with government agencies.
- Evolving evidence on efficacy across variants.
Regulatory and Policy Impact
The FDA has limited the emergency use authorization (EUA) for casirivimab/imdevimab against newer variants. If restrictions tighten or product approvals decline, demand could fall substantially, pressuring prices downward.
Supply Chain and Distribution Factors
The infusion-based nature impacts market access. Infrastructure for outpatient administration, cold storage, and trained personnel influence utilization and pricing models.
Summary
Casirivimab/imdevimab remains a significant antibody treatment for COVID-19, but its market and pricing landscape face challenges over the next two years. Pricing remains relatively stable but is vulnerable to variant-driven efficacy changes, regulatory shifts, and competitive oral therapeutics.
Key Takeaways
- The U.S. market for NDC 62559-0680 centers around 300,000–600,000 eligible patients monthly, with a total potential revenue above $2 billion annually at list prices.
- Actual prices vary from about $850 to $2,100 per dose, influenced by negotiations, payer programs, and discounts.
- Market outlook depends heavily on variant impact, regulatory decisions, and competitors' therapies.
- Price projections suggest a decline in potential revenue if variants diminish efficacy or treatments are replaced by oral options.
- Supply chain and administration infrastructure are critical to expanding utilization and maintaining pricing power.
FAQs
-
What is the primary indication for NDC 62559-0680?
It is authorized for treatment of COVID-19 in non-hospitalized patients at high risk of severe disease.
-
How does the efficacy of casirivimab/imdevimab compare against variants?
Effectiveness decreases notably against Omicron and its subvariants, limiting use in some regions.
-
What factors influence pricing negotiations for this drug?
Payer contracts, volume discounts, regional regulations, and competing therapies.
-
Will prices decrease as newer therapies emerge?
Likely, especially if oral antivirals prove more convenient and effective against circulating variants.
-
Are there policy changes expected that could impact the market?
Yes, regulatory adjustments restricting use against certain variants can reduce demand and pricing.
References
[1] CDC COVID-19 Treatment Guidelines, July 2023.
[2] Wholesale pricing sources, March 2023.
